-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptevo Therapeutics Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine In Newly Diagnosed AML Patients

Benzinga·03/10/2026 12:16:16
Listen to the news

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine

SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients who are either elderly or unfit for intensive chemotherapy. In data from two trials, the combination has demonstrated robust clinical activity, delivering an 86% clinical benefit rate (CR/CRi/PR*)with zero patients experiencing the common symptom of cytokine release syndrome (CRS). These data support an emerging efficacy profile coupled with differentiated patient safety and tolerability that is additive to the current AML standard-of-care therapy.